Day 2 tests: private provider requirements  7. —(1) For the purposes of paragraph 6(1)(b)(iii), a private provider complies with this  paragraph where—  (2) For the purposes of sub-paragraph (1)(m), “single end-to-end testing service” has the  meaning given in paragraph 3(2)(c) of Schedule 10.  62 (a) they comply with the requirements of paragraph 3(1)(a) and (e) to (h) of Schedule 10 as if  any reference in those provisions to an appropriate test were a reference to a day 2 test;  (b) if the provider is a laboratory that conducts diagnostic test evaluation for testing in  accordance with this Schedule, they have made a declaration to the Department of Health  and Social Care that they meet the minimum standards for private sector-provided testing  at https://support-covid-19-testing.dhsc.gov.uk/InternationalTesting;  (c) they have provided the Department of Health and Social Care with a list of all  organisations that they work with (whether by sub-contract or otherwise) to carry out the  testing service or to carry out genomic sequencing, indicating the nature of the service  that each organisation is providing, and kept that list updated as appropriate;  (d) the person responsible for the taking of samples meets the relevant requirements for  accreditation to ISO standard 15189 or ISO/IEC standard 17025 in respect of the taking  of samples;  (e) the laboratory used by the test provider for the processing of samples meets the relevant  requirements for ISO standard 15189 or ISO/IEC standard 17025 in respect of the  evaluation of the established molecular detection method and the genomic sequencing of  samples;  (f) they receive the information required by paragraph 10(3) or (4) (as appropriate), and if  they administer the test to P, they do so no later than the end of the second day after the  day on which P arrived in England;  (g) each day, they notify the Secretary of State in writing of—  (i) the number of tests they sold on that day, and  (ii) in relation to each test sold on that day—  (aa) the date of the arrival in England of the person in respect of whom the test  was sold, and  (bb) whether the person in respect of whom the test was sold is a category 1 arrival  or not;  (h) they sequence each sample with a cycle threshold less than 30 (equivalent to ~1,000 viral  genome copies per millilitre);  (i) in respect of the sequencing of samples, they must secure a reference genome coverage  breadth of at least 50% and at least 30 times coverage;  (j) on a request by the Secretary of State or the COVID-19 Genomics UK Consortium, they  make samples available for the purpose of dual sequencing;  (k) they preserve and transport samples in a manner that enables genome sequencing;  (l) they have in place a process to remove human reads from any data submitted in a  notification to Public Health England pursuant to the Health Protection (Notification)  Regulations 2010; and  (m) if they arrange with another person (“X”) for X to carry out any element of the single  end-to-end testing service on their behalf, the test provider ensures that X complies with  the following so far as relevant to the carrying out of that element—  (i) paragraph 3(1)(e) to (h) of Schedule 10 as applied by paragraph (a) of this sub- paragraph,  (ii) paragraph (c) to (l) of this sub-paragraph,  (iii) paragraph 11(2), (3) and (4). 